GlassScriptPhysician profile
Wen Liu
NPI 1336328202
$6,068.70
in general payments reported to CMS, 2019-2025
36 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $1,050 · 2021: $1,394 · 2022: $1,251 · 2023: $630 · 2024: $434 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,699.18 | 2019-2024 | Lokelma, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $870.13 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $364.54 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $341.62 | 2019-2024 | Dificid, Verquvo |
| Novartis Pharmaceuticals Corporation | $283.73 | 2019-2025 | |
| Novo Nordisk INC | $264.08 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $235.29 | 2019-2025 | |
| Astellas Pharma US INC | $218.26 | 2021-2023 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.90 | 2020-2022 | |
| Lilly USA, LLC | $152.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $131.86 | 2019-2023 | |
| Tactile Systems Technology INC | $130.47 | 2022 | |
| Paratek Pharmaceuticals, INC. | $126.47 | 2019-2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $113.32 | 2022-2023 | |
| Antares Pharma, INC. | $103.91 | 2021-2023 | Tlando, Xyosted, Nocdurna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $80.11 | 2023-2025 | Terlivaz |
| Medtronic, INC. | $76.80 | 2021-2025 | Symplicity G3 |
| Phathom Pharmaceuticals, INC. | $68.53 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $64.83 | 2025 | Gemtesa |
| Melinta Therapeutics, LLC | $63.93 | 2019 | |
| Shire North American Group INC | $60.65 | 2019 | |
| Abbott Laboratories | $58.90 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $57.60 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.52 | 2020-2021 | |
| Daiichi Sankyo INC. | $44.30 | 2019-2021 | |
| Ucb, INC. | $39.54 | 2024 | Nayzilam |
| Otsuka America Pharmaceutical, INC. | $38.70 | 2019 | |
| Allergan, INC. | $30.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.01 | 2022 | |
| Corcept Therapeutics | $20.16 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $18.66 | 2021 | |
| Amgen INC. | $18.15 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.78 | 2025 | Monoferric |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Esperion Therapeutics, INC. | $14.89 | 2020 | |
| Horizon Therapeutics Plc | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.